Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04145297
Title Ulixertinib (BVD-523) and Hydroxychloroquine in Patients w Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas (UTAH)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors University of Utah
Indications

gastrointestinal system cancer

Therapies

Hydroxychloroquine + Ulixertinib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST